PSA Progression clinical trials at UCSD
1 in progress, 1 open to new patients
Olaparib With or Without Cediranib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
open to eligible males ages 18 years and up
This randomized phase II trial studies how well olaparib with or without cediranib works in treating patients with castration-resistant prostate cancer that has spread to other places in the body. Olaparib and cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
La Jolla, California and other locations